These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8993793)

  • 41. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
    Schatzl G; Madersbacher S; Gsur A; Preyer M; Haidinger G; Haitel A; Vutuc C; Micksche M; Marberger M
    Prostate; 2002 Jul; 52(2):130-8. PubMed ID: 12111704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
    Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is low serum free testosterone a marker for high grade prostate cancer?
    Hoffman MA; DeWolf WC; Morgentaler A
    J Urol; 2000 Mar; 163(3):824-7. PubMed ID: 10687985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hormones and prostate cancer: where do we go from here?
    Hsing AW
    J Natl Cancer Inst; 1996 Aug; 88(16):1093-5. PubMed ID: 8757182
    [No Abstract]   [Full Text] [Related]  

  • 46. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.
    Ross RK; Bernstein L; Lobo RA; Shimizu H; Stanczyk FZ; Pike MC; Henderson BE
    Lancet; 1992 Apr; 339(8798):887-9. PubMed ID: 1348296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum androgens and prostate cancer.
    Nomura AM; Stemmermann GN; Chyou PH; Henderson BE; Stanczyk FZ
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):621-5. PubMed ID: 8824364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Origin and significance of plasma androsterone glucuronide levels: a parameter of adrenal androgen secretion and hepatic 5 alpha-reductase activity.
    Giagulli VA; Giorgino R; Vermeulen A
    J Clin Endocrinol Metab; 1993 Apr; 76(4):918-23. PubMed ID: 8473406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Faydaci G; Kuyumcuoglu U
    BJU Int; 2010 Jan; 105(2):281; author reply 281. PubMed ID: 20078600
    [No Abstract]   [Full Text] [Related]  

  • 50. Race and prostate cancer.
    Harv Mens Health Watch; 1999 Jul; 3(12):7. PubMed ID: 10368543
    [No Abstract]   [Full Text] [Related]  

  • 51. Adjusted odds ratios under nondifferential misclassification: application to prostate cancer.
    Godley PA; Schell MJ
    J Clin Epidemiol; 1999 Feb; 52(2):129-36. PubMed ID: 10201653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men.
    Watts EL; Appleby PN; Albanes D; Black A; Chan JM; Chen C; Cirillo PM; Cohn BA; Cook MB; Donovan JL; Ferrucci L; Garland CF; Giles GG; Goodman PJ; Habel LA; Haiman CA; Holly JMP; Hoover RN; Kaaks R; Knekt P; Kolonel LN; Kubo T; Le Marchand L; Luostarinen T; MacInnis RJ; Mäenpää HO; Männistö S; Metter EJ; Milne RL; Nomura AMY; Oliver SE; Parsons JK; Peeters PH; Platz EA; Riboli E; Ricceri F; Rinaldi S; Rissanen H; Sawada N; Schaefer CA; Schenk JM; Stanczyk FZ; Stampfer M; Stattin P; Stenman UH; Tjønneland A; Trichopoulou A; Thompson IM; Tsugane S; Vatten L; Whittemore AS; Ziegler RG; Allen NE; Key TJ; Travis RC
    PLoS One; 2017; 12(12):e0187741. PubMed ID: 29281666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.
    Wang K; Chen X; Bird VY; Gerke TA; Manini TM; Prosperi M
    Int J Cancer; 2017 Nov; 141(9):1783-1793. PubMed ID: 28699177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model.
    Xu X; Chen X; Hu H; Dailey AB; Taylor BD
    BMC Cancer; 2015 Oct; 15():806. PubMed ID: 26502956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.
    Li J; Mercer E; Gou X; Lu YJ
    Am J Cancer Res; 2013; 3(2):127-51. PubMed ID: 23593537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cross-sectional study of the association of age, race and ethnicity, and body mass index with sex steroid hormone marker profiles among men in the National Health and Nutrition Examination Survey (NHANES III).
    Ritchey J; Karmaus W; Sabo-Attwood T; Steck SE; Zhang H
    BMJ Open; 2012; 2(5):. PubMed ID: 23043125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.
    ; Roddam AW; Allen NE; Appleby P; Key TJ
    J Natl Cancer Inst; 2008 Feb; 100(3):170-83. PubMed ID: 18230794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies.
    Eaton NE; Reeves GK; Appleby PN; Key TJ
    Br J Cancer; 1999 Jun; 80(7):930-4. PubMed ID: 10362098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera.
    Guess HA; Friedman GD; Sadler MC; Stanczyk FZ; Vogelman JH; Imperato-McGinley J; Lobo RA; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):21-4. PubMed ID: 8993793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway.
    Vatten LJ; Ursin G; Ross RK; Stanczyk FZ; Lobo RA; Harvei S; Jellum E
    Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):967-9. PubMed ID: 9367072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.